New York Life Investment Management LLC lessened its position in Penumbra, Inc. (NYSE:PEN – Free Report) by 74.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,495 shares of the company’s stock after selling 15,822 shares during the period. New York Life Investment Management LLC’s holdings in Penumbra were worth $1,749,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in PEN. BlackRock Inc. acquired a new stake in Penumbra in the 2nd quarter valued at approximately $1,356,953,000. Whitebox Advisors LLC acquired a new position in Penumbra during the 1st quarter worth $146,125,000. Bank of America Corp DE acquired a new position in Penumbra during the 2nd quarter worth $83,995,000. Amundi grew its stake in shares of Penumbra by 302.9% in the first quarter. Amundi now owns 345,758 shares of the company’s stock worth $113,537,000 after purchasing an additional 259,936 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of Penumbra during the second quarter valued at $74,305,000. 88.88% of the stock is currently owned by institutional investors and hedge funds.
Penumbra Price Performance
Shares of Penumbra stock traded up $0.19 during trading on Friday, hitting $320.96. The stock had a trading volume of 237,595 shares, compared to its average volume of 396,666. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.89 and a quick ratio of 3.92. The firm has a market cap of $12.65 billion, a P/E ratio of 80.85 and a beta of 0.71. The business has a fifty day moving average of $320.18 and a two-hundred day moving average of $326.09. Penumbra, Inc. has a fifty-two week low of $274.55 and a fifty-two week high of $362.41.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on PEN shares. Zacks Research raised shares of Penumbra from a “strong sell” rating to a “hold” rating in a report on Monday, August 24th. Weiss Ratings raised shares of Penumbra from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, October 30th. Three research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the stock. According to MarketBeat, Penumbra has a consensus rating of “Hold” and a consensus target price of $367.07.
Read Our Latest Stock Report on PEN
About Penumbra
Penumbra, Inc. is a medical technology company that develops and markets devices for treating vascular conditions. Its products are used in neurovascular procedures, including the treatment of ischemic stroke and aneurysms, and in peripheral vascular procedures involving conditions such as pulmonary embolism and deep vein thrombosis. The company’s offerings include aspiration and mechanical thrombectomy systems, embolization coils, and related catheter-based devices. Penumbra was founded in 2004 and is headquartered in Alameda, California.
Recommended Stories
- Five stocks we like better than Penumbra
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Want to see what other hedge funds are holding PEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Penumbra, Inc. (NYSE:PEN – Free Report).
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.
